{"id":1400,"date":"2026-09-21T22:19:34","date_gmt":"2026-09-21T14:19:34","guid":{"rendered":"http:\/\/www.puriactives.com\/en\/?p=1400"},"modified":"2026-09-21T22:19:34","modified_gmt":"2026-09-21T14:19:34","slug":"acnezero","status":"publish","type":"post","link":"http:\/\/www.puriactives.com\/en\/?p=1400","title":{"rendered":"AcneZero"},"content":{"rendered":"

<\/h2>\n

PuriActives\u00ae AcneZero \u2014 Multi-Pathway Botanical Blemish Care System<\/p>\n

<\/p>\n

PURIACTIVES\u00ae MULTI-BOTANICAL BLEMISH CARE SYSTEM<\/p>\n

AcneZero \u75d8\u5fc5\u6e05<\/h2>\n

A Multi-Pathway, Botanical Synergy System for Blemish-Prone Skin<\/p>\n

From Single-Target to Multi-Pathway Care<\/p>\n

SebumInflammationOxidative StressMicrobiomeSoothing & Barrier<\/p>\n

PuriPharm Co., Ltd.B2B technical & marketing material \u00b7 For cosmetics industry professionals only<\/p>\n

CONTENTS<\/h2>\n

A complete evidence chain from mechanism to commercial value<\/p>\n\n\n\n\n\n\n\n
01<\/td>\nUnderstanding Blemish-Prone Skin \u2014 The Mechanism Map of a Multifactorial Skin Condition<\/td>\n<\/tr>\n
02<\/td>\nProduct Overview \u2014 Composition, Positioning & the Phospholipid-Based Active System<\/td>\n<\/tr>\n
03<\/td>\nThe Five Axes \u2014 Ingredient-Level Scientific Evidence & Mechanisms<\/td>\n<\/tr>\n
04<\/td>\nBotanical Actives in Focus \u2014 Scientific Profiles of Seven Plant Extracts<\/td>\n<\/tr>\n
05<\/td>\nSynergy \u00b7 Claims \u00b7 Applications \u2014 From Evidence Grading to B2B Value<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

Evidence grading: A = AcneZero’s own product data; B = published ingredient literature; C = reasonable extrapolation from ingredient information. Ingredient-level literature results are not equivalent to finished-product efficacy.<\/p>\n

01<\/b><\/p>\n

Understanding Blemish-Prone Skin<\/h2>\n

Acne is not a simple “bacterial problem.” It is a multifactorial condition in which sebum production, follicular keratinization, microbes, inflammatory cascades and oxidative stress intertwine \u2014 and this is exactly where single-target solutions reach their limits.<\/p>\n

In this chapter \uff5c The acne pathogenesis network \u00b7 The oxidative-stress amplifier \u00b7 The limits of single-target care<\/p>\n

Acne Pathogenesis: A Network of Five Mutually Amplifying Pathways<\/h3>\n

01 UNDERSTANDING BLEMISH-PRONE SKIN \uff5c ACNE PATHOGENESIS<\/p>\n\n\n\n\n\n\n\n
\u2460 Excess sebum production<\/td>\nIGF-1 \/ androgen signaling drives sebaceous lipid synthesis via PI3K\u2013Akt\u2013mTORC1, providing the substrate for downstream oxidation and microbial imbalance.<\/td>\n<\/tr>\n
\u2461 Abnormal follicular keratinization<\/td>\nLipid peroxides (e.g., squalene monohydroperoxide) promote keratinocyte hyperproliferation; the follicle becomes plugged and microcomedones form.<\/td>\n<\/tr>\n
\u2462 Microbes & dysbiosis<\/td>\nCutibacterium acnes (formerly Propionibacterium acnes) overgrows in anaerobic, lipid-rich follicles and activates innate immunity via TLR2; biofilms and resistant strains make management harder.<\/td>\n<\/tr>\n
\u2463 Inflammatory cascade amplification<\/td>\nThe TLR2\uff0fTLR4 \u2192 NF-\u03baB\uff0fMAPK pathway drives the release of IL-1\u03b2, IL-6, IL-8 and TNF-\u03b1, determining redness, swelling, pain and the risk of post-inflammatory hyperpigmentation.<\/td>\n<\/tr>\n
\u2464 Oxidative stress & lipid peroxidation<\/td>\nUV, pollution and microbes jointly trigger sebum oxidation; oxidized lipids in turn aggravate abnormal keratinization and inflammation \u2014 the network’s “amplifier.”<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

Mechanistic framework: Cong TX, et al. Arch Dermatol Res. 2019;311(5):337-349. DOI:10.1007\/s00403-019-01908-x; Dr\u00e9no B, et al. J Eur Acad Dermatol Venereol. 2018;32(Suppl 2):5-14; Condr\u00f2 G, et al. Pharmaceuticals. 2023;16(12):1704.<\/p>\n

The Underestimated Amplifier: Squalene Peroxidation<\/h3>\n

01 UNDERSTANDING BLEMISH-PRONE SKIN \uff5c SQUALENE PEROXIDATION<\/p>\n

Squalene accounts for about 10\u201315%<\/b> of sebum lipids, and its multiple double bonds make it highly prone to oxidation into squalene monohydroperoxide \u2014 a strongly comedogenic compound. In vivo studies confirm that both squalene and its peroxidized forms are significantly higher in acne-prone skin than in healthy skin, correlating positively with sebum output and porphyrin intensity; acne-prone skin also shows higher transepidermal water loss (TEWL)<\/b>, indicating an impaired barrier.<\/p>\n

<\/p>\n

Reading the chart: squalene peroxidation is higher in inflammatory lesion areas than in non-inflammatory areas \u2014 lipid peroxidation moves in the same direction as inflammation, forming a vicious cycle of “oxidation \u2192 inflammation \u2192 more oxidation.”<\/p>\n

Implications for formulation strategy<\/b><\/p>\n

\u00b7 “Antibacterial only” cannot break the oxidation cycle \u2014 antioxidant and anti-lipid-peroxidation design must be part of anti-blemish formulations;\u00b7 The barrier of blemish-prone skin is already compromised, so efficacy systems must be both low-irritation and barrier-friendly;\u00b7 Oxidation management is also linked to post-inflammatory hyperpigmentation (PIH) risk \u2014 the shared foundation of “fighting acne” and “post-blemish recovery.”<\/p>\n

Data redrawn from: Condr\u00f2 G, Sciortino R, Perugini P. Squalene peroxidation and biophysical parameters in acne-prone skin: a pilot “in vivo” study. Pharmaceuticals (Basel). 2023;16(12):1704. DOI:10.3390\/ph16121704 (mechanistic background literature, not data on this product)<\/p>\n

The Ceiling of Single-Target Solutions Is Exactly the Opportunity for Multi-Pathway Care<\/h3>\n

01 UNDERSTANDING BLEMISH-PRONE SKIN \uff5c UNMET NEEDS<\/p>\n\n\n\n\n
Challenges of traditional single-pathway approaches<\/th>\nThe answer from multi-pathway botanical synergy<\/th>\n<\/tr>\n
Antibiotic pathway \u2014 C. acnes resistance keeps rising; long-term use faces resistance and microbiome disturbance;Retinoid pathway \u2014 effective for keratinization, but irritation, dryness and peeling limit use on sensitive, blemish-prone skin;Single-botanical pathway \u2014 usually covers only “antibacterial” or “anti-inflammatory,” hardly matching acne’s multifactorial mechanism;The overlooked link \u2014 oxidative stress and barrier damage have long been absent from the anti-acne narrative, yet directly affect recurrence and post-blemish condition.<\/td>\n\u25cf Division of labor across ingredients: different botanicals act on sebum, inflammation, oxidation, microbes and the barrier \u2014 covering the mechanistic network rather than a single point;\u25cf Non-antibiotic antimicrobial strategy: plant-derived actives (e.g., berberine-type alkaloids) show C. acnes inhibition and anti-biofilm potential in the literature, avoiding the antibiotic-resistance narrative;\u25cf Cosmetics-compliant storytelling: framed as “blemish-prone skin care \/ oil control \/ soothing,” within cosmetic claim boundaries;\u25cf Gentle enough for daily use: product safety data support no skin irritation and no eye irritation, suiting long-term care scenarios.<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

Note: the left column is background at the level of literature and industry consensus, used to explain formulation design logic; it is not an evaluation of any pharmaceutical regimen. The “non-antibiotic antimicrobial strategy” on the right is ingredient-level literature evidence (Grade B).<\/p>\n

Background: Cong TX, et al. Arch Dermatol Res. 2019;311(5):337-349; Sun L, et al. Front Microbiol. 2023;14:1276383. DOI:10.3389\/fmicb.2023.1276383; product safety: AcneZero MSDS v1.1 (Grade A)<\/p>\n

02<\/b><\/p>\n

Product Overview \uff5c AcneZero<\/h2>\n

Seven botanical actives \u00d7 a phospholipid-based active system: with the ingredient list and MSDS as the highest factual basis, defining a modern anti-blemish ingredient by mechanistic division of labor rather than “single-point sterilization.”<\/p>\n

In this chapter \uff5c Positioning \u00b7 Eleven-component formula \u00b7 Phospholipid-based active system \u00b7 The five-axis master model<\/p>\n

Positioning: A Multi-Pathway Ingredient for Blemish-Prone Skin Management<\/h3>\n

02 PRODUCT OVERVIEW \uff5c PRODUCT IDENTITY<\/p>\n

PuriActives\u00ae AcneZero is a multi-botanical anti-blemish ingredient developed by PuriPharm for cosmetics customers worldwide. Its active core combines seven botanical extracts<\/b> \u2014 Canarium album (olive) leaf extract, bioflavonoids, Salvia miltiorrhiza extract, Gardenia jasminoides fruit extract, Mahonia fortunei extract, silymarin, and Stevia rebaudiana leaf\/stem extract \u2014 carried by a phospholipid-based active system, covering five axes: sebum \u2013 inflammation \u2013 oxidation \u2013 microbiome \u2013 barrier<\/b>. It is not a “single sterilizing molecule,” but an evidence-graded, multi-pathway solution.<\/p>\n\n\n\n\n\n\n\n\n\n\n\n
Product information (per MSDS v1.1)<\/th>\n<\/tr>\n
Trade name<\/td>\nAcneZero \u75d8\u5fc5\u6e05 (PuriActives\u00ae brand)<\/td>\n<\/tr>\n
Intended use<\/td>\nCosmetic skincare ingredient (B2B industrial use)<\/td>\n<\/tr>\n
Appearance & odor<\/td>\nYellow liquid, characteristic odor<\/td>\n<\/tr>\n
Solubility<\/td>\nWater-soluble (20\u00b0C)<\/td>\n<\/tr>\n
Storage<\/td>\n4\u201325\u00b0C, protect from light<\/td>\n<\/tr>\n
Safety<\/td>\nNo skin irritation, no eye irritation (MSDS data, Grade A)<\/td>\n<\/tr>\n
Regulatory status<\/td>\nListed in China’s Inventory of Existing Chemical Substances (IECIC)<\/td>\n<\/tr>\n
Document version<\/td>\nMSDS v1.1 (2019-07-13)<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

POSITIONING IN ONE SENTENCE<\/p>\n

“From single-target anti-acne to multi-pathway blemish-prone skin management.”<\/b><\/p>\n

\u00b7 Target customers: cosmetics brands, formulators, OEM\/ODM R&D teams\u00b7 Suitable dosage forms: serums, toners, lotions, masks and other water-based systems\u00b7 Claim framework: oil control \u00b7 soothing \u00b7 microbiome balance \u00b7 antioxidant \u00b7 barrier support \u00b7 post-blemish tone care<\/p>\n

Product information: PuriPharm AcneZero MSDS v1.1 and AcneZero Ingredient List (internal documents, Grade-A factual basis). Please confirm recommended dosage and compatibility parameters with the PuriPharm technical team.<\/p>\n

Eleven Components: A Formula You Can Read Mechanistically<\/h3>\n

02 PRODUCT OVERVIEW \uff5c COMPOSITION<\/p>\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n
Component (INCI)<\/th>\nCAS No.<\/th>\nTypical value (%)<\/th>\n<\/tr>\n
Canarium Album Leaf Extract<\/td>\n\u2014<\/td>\n2.5<\/td>\n<\/tr>\n
Bioflavonoids<\/td>\n61788-55-4<\/td>\n3.0<\/td>\n<\/tr>\n
Salvia Miltiorrhiza Extract<\/td>\n90106-50-6<\/td>\n2.5<\/td>\n<\/tr>\n
Gardenia Jasminoides Fruit Extract<\/td>\n92457-01-7<\/td>\n3.5<\/td>\n<\/tr>\n
Mahonia Fortunei (Chinese mahonia) Extract<\/td>\n\u2014<\/td>\n3.0<\/td>\n<\/tr>\n
Silymarin<\/td>\n22888-70-6<\/td>\n0.5<\/td>\n<\/tr>\n
Stevia Rebaudiana Leaf\/Stem Extract<\/td>\n91722-21-3<\/td>\n5.0<\/td>\n<\/tr>\n
Phospholipids<\/td>\n123456-35-0<\/td>\n5.0<\/td>\n<\/tr>\n
Glycerin<\/td>\n56-81-5<\/td>\n38.0<\/td>\n<\/tr>\n
Propylene Glycol<\/td>\n57-55-6<\/td>\n31.5<\/td>\n<\/tr>\n
Aqua (Water)<\/td>\n7732-18-5<\/td>\n5.5<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

Formula structure (grouped by typical values)<\/b><\/p>\n

<\/p>\n

\u00b7 Botanical actives total 20% and phospholipids 5%, forming the functional “active + delivery” layer;\u00b7 Glycerin, propylene glycol and water form the humectant solvent base, also responsible for mildness and system stability.<\/p>\n

Data source: PuriPharm AcneZero Ingredient List and AcneZero MSDS v1.1 (Grade A \u2014 the highest factual basis, never modified for marketing). Values shown are typical values from the company’s ingredient list; specification ranges are detailed in the product ingredient list.<\/p>\n

The Phospholipid-Based Active System: A Classic Skin-Affinity Delivery Strategy<\/h3>\n

02 PRODUCT OVERVIEW \uff5c PHOSPHOLIPID-BASED ACTIVE SYSTEM<\/p>\n

AcneZero builds its active-carrier system on 5% phospholipids<\/b>. Phospholipids share a natural affinity with stratum corneum lipids and are a classic skin-friendly delivery and stabilization strategy in cosmetic science, helping water- and oil-soluble botanical actives coexist stably in one system.<\/p>\n

\u25cf Skin-lipid affinity<\/b>: the phospholipid bilayer is homologous to stratum corneum lipids, favoring spreading and retention of actives on the skin surface;\u25cf Classic delivery evidence<\/b>: as early as 1980, Mezei and Gulasekharam showed that a phospholipid system (liposomal lotion) increased skin delivery of triamcinolone acetonide to 4\u20135\u00d7<\/b> that of an ointment base \u2014 laying the literature foundation for phospholipids in dermal delivery;\u25cf Multi-phase stability<\/b>: the emulsifying and dispersing capacity of phospholipids supports the uniform coexistence of seven botanicals with the water-based vehicle;\u25cf Barrier-friendly<\/b>: phospholipids themselves are mild, skin-lipid-related ingredients, matching the fragile-barrier needs of blemish-prone skin.<\/p>\n

Hydrophilic heads \u00b7 facing the water phaseHydrophobic tails \u00b7 carrying lipophilic activesHydrophilic heads \u00b7 facing the water phase<\/p>\n

Schematic: phospholipid bilayer structure (self-drawn illustration)<\/p>\n

Claim boundary: AcneZero is a Phospholipid-based Active System. This material makes no liposome, nanovesicle or nano-delivery claims for it; liposome-related literature is cited only as classic supporting evidence for the dermal-delivery value of phospholipid systems.<\/p>\n

Reference: Mezei M, Gulasekharam V. Liposomes \u2014 a selective drug delivery system for the topical route of administration. Life Sci. 1980;26:1473-1477 (Grade-B background evidence). Phospholipid content: AcneZero Ingredient List (Grade A).<\/p>\n

The AcneZero Five-Axis Model<\/h3>\n

02 PRODUCT OVERVIEW \uff5c MULTI-PATHWAY MODEL<\/p>\n

AcneZero \uff5c Seven botanicals \u00d7 phospholipid-based system<\/b><\/p>\n\n\n\n\n\n\n\n
A1 Sebum management<\/td>\nMahonia (berberine) \u00b7 olive leaf \u00b7 bioflavonoidsTargeting SREBP-1\uff0fPPAR-\u03b3 lipid-synthesis signaling<\/td>\n<\/tr>\n
A2 Inflammation management<\/td>\nSalvia \u00b7 gardenia fruit \u00b7 bioflavonoids \u00b7 olive leaf \u00b7 steviaTargeting the TLR2\/4 \u2192 NF-\u03baB\uff0fMAPK inflammatory cascade<\/td>\n<\/tr>\n
A3 Oxidative-stress management<\/td>\nSilymarin \u00b7 bioflavonoids \u00b7 olive leaf \u00b7 steviaScavenging free radicals and inhibiting sebum lipid peroxidation<\/td>\n<\/tr>\n
A4 Microbiome management<\/td>\nMahonia (berberine) \u00b7 salvia \u00b7 silymarinNon-antibiotic C. acnes management and biofilm inhibition<\/td>\n<\/tr>\n
A5 Soothing & barrier support<\/td>\nStevia \u00b7 phospholipids \u00b7 gardenia fruitTight-junction protein and skin-friendly lipid support<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

The model summarizes mechanistic division of labor based on published ingredient literature (combined Grade B\/C evidence); it is not a clinical-trial conclusion for this product. Axis-by-axis evidence is detailed in Chapter 3. Composition: AcneZero Ingredient List (Grade A).<\/p>\n

03<\/b><\/p>\n

The Five Axes \u00b7 Ingredient-Level Scientific Evidence<\/h2>\n

Each axis answers a formulation question: which ingredient, acting on which step, with evidence from where, and how strong. All data are annotated with study models and literature sources.<\/p>\n

In this chapter \uff5c A1 Sebum \u00b7 A2 Inflammation \u00b7 A3 Oxidative stress \u00b7 A4 Microbiome \u00b7 A5 Soothing & barrier<\/p>\n

Axis 1 \u00b7 Sebum Management: Regulating Lipid-Synthesis Signaling<\/h3>\n

03 THE FIVE AXES \uff5c AXIS 1 \u00b7 SEBUM CONTROL<\/p>\n

Key signaling axis of sebum synthesis (mechanistic background)<\/p>\n

IGF-1 \/ androgens \u2192 PI3K\u2013Akt \u2192 SREBP-1\uff0fPPAR-\u03b3 \u2192 Excess sebum<\/p>\n

Ingredient-level evidence (sebocyte models)<\/b><\/p>\n

Berberine (marker compound of Mahonia)<\/b>\uff5c Grade BIn SZ95 human sebocytes, 40 \u03bcM berberine significantly downregulated the key lipogenic enzymes FASN and DGAT1, reduced fatty-acid and triglyceride secretion, and inhibited NF-\u03baB p65 activation (J Inflamm Res, 2025).<\/p>\n

Olive leaf extract<\/b>\uff5c Grade C (literature species Olea europaea, extrapolation reference)In SEB-1 sebocytes it significantly inhibited linoleic-acid-induced lipid accumulation without cytotoxicity, and downregulated AKT\uff0fERK phosphorylation and PPAR-\u03b3\uff0fSREBP-1 expression (Curr Issues Mol Biol, 2026).<\/p>\n

Mechanistic benchmark: EGCG (polyphenol)<\/b>\uff5c literature benchmarkReduced sebum synthesis in SEB-1 cells via AMPK\u2013SREBP-1 and improved acne in an 8-week randomized split-face human trial (J Invest Dermatol, 2013) \u2014 validating the clinical feasibility of the “botanical polyphenols regulate sebum” pathway.<\/p>\n

Division of labor in AcneZero:<\/b> Mahonia extract (berberine source; botanical basis in Chapter 4) \uff5c olive leaf extract (polyphenols; sebum-regulation extrapolation reference) \uff5c bioflavonoids (polyphenol-family synergy)<\/p>\n

Sources: Berberine inhibits acne-related lipid secretion and inflammation by regulating the hsa-miR-3150a-3p\/TP53 pathway. J Inflamm Res. 2025; Kim J, et al. Curr Issues Mol Biol. 2026;48(6):549. DOI:10.3390\/cimb48060549; Yoon JY, et al. J Invest Dermatol. 2013;133(2):429-440; Cong TX, et al. 2019 (signaling-axis background)<\/p>\n

Axis 2 \u00b7 Inflammation Management: Intercepting the TLR \u2192 NF-\u03baB Cascade<\/h3>\n

03 THE FIVE AXES \uff5c AXIS 2 \u00b7 INFLAMMATION<\/p>\n

The C. acnes-triggered inflammatory cascade (mechanistic background)<\/p>\n

C. acnes & its products \u2192 TLR2\uff0fTLR4 \u2192 NF-\u03baB\uff0fMAPK \u2192 IL-1\u03b2 \u00b7 IL-6 \u00b7 IL-8 \u00b7 TNF-\u03b1 \u2192 Redness \u00b7 lesions \u00b7 PIH<\/p>\n

Interception point 1: the receptor layer (TLR2\uff0fTLR4 downregulation)Quercetin (representative bioflavonoid)<\/b>\uff5c Grade B\u3000In C. acnes-stimulated HaCaT keratinocytes, THP-1 and RAW264.7 cells, it inhibited inflammatory cytokine release and downregulated TLR2, p38\uff0fERK\uff0fJNK phosphorylation and MMP-9, with in vivo anti-inflammatory validation in a mouse-ear model (Int Immunopharmacol, 2021).<\/p>\n

Interception point 2: the signaling layer (TAK1\uff0fNF-\u03baB inhibition)Tanshinone IIA (marker compound of Salvia)<\/b>\uff5c Grade B\u3000Concentration-dependently inhibited LPS-induced MCP-1, IL-6, TNF-\u03b1 and NO production, downregulated TLR4 expression, and suppressed TAK1 phosphorylation and NF-\u03baB p65 nuclear translocation (Int J Mol Med, 2019).<\/p>\n

Why “multiple interception points” beat single-point inhibition:<\/b>\u00b7 Acne inflammation is driven in parallel by multiple receptor\u2013signaling routes; blocking a single node is easily bypassed;\u00b7 In the literature, AcneZero’s botanicals act at different levels \u2014 TLR2 (quercetin), TLR4\uff0fTAK1 (tanshinone IIA, geniposide), NF-\u03baB (stevioside, berberine);\u00b7 This multi-point division of labor is the design logic of the product’s inflammation-management axis (see the evidence matrix below).<\/p>\n

Sources: Lim HJ, et al. Int Immunopharmacol. 2021;96:107557. DOI:10.1016\/j.intimp.2021.107557; Meng Z, et al. Int J Mol Med. 2019;43(4):1847-1858. DOI:10.3892\/ijmm.2019.4100; cascade background: Cong TX, et al. 2019; Dr\u00e9no B, et al. 2018<\/p>\n

Inflammation-Management Evidence Matrix: Five Ingredients, Four Interception Layers<\/h3>\n

03 THE FIVE AXES \uff5c AXIS 2 \u00b7 EVIDENCE MATRIX<\/p>\n\n\n\n\n\n\n\n\n
Ingredient \/ marker<\/th>\nStudy model<\/th>\nKey results<\/th>\nReference (Grade B)<\/th>\n<\/tr>\n
Quercetin (representative bioflavonoid)<\/td>\nC. acnes-stimulated HaCaT\uff0fTHP-1\uff0fRAW264.7; mouse-ear model<\/td>\n\u2193IL-6\uff0fIL-8\uff0fTNF-\u03b1; \u2193TLR2, p38\uff0fERK\uff0fJNK, MMP-9<\/td>\nLim et al. Int Immunopharmacol. 2021<\/td>\n<\/tr>\n
Tanshinone IIA (Salvia marker)<\/td>\nLPS-stimulated vascular smooth muscle cells<\/td>\n\u2193MCP-1\uff0fIL-6\uff0fTNF-\u03b1\uff0fNO; \u2193TLR4\u2013TAK1\u2013NF-\u03baB<\/td>\nMeng et al. Int J Mol Med. 2019<\/td>\n<\/tr>\n
Gardenia fruit extract \/ geniposide<\/td>\nLPS-induced inflammation models; in vivo zebrafish model<\/td>\n\u2193IL-1\u03b2\uff0fIL-6\uff0fTNF-\u03b1; \u2193TLR4 signaling, NF-\u03baB p65\uff0fMAPK<\/td>\nChen et al. Exp Ther Med. 2021; Song et al. Inflammation. 2014<\/td>\n<\/tr>\n
Stevioside (stevia marker)<\/td>\nCellular oxidative-inflammation model<\/td>\n\u2193IL-6\uff0fIL-8\uff0fTNF-\u03b1; \u2193NF-\u03baB\uff0fI\u03baB\uff0fERK1\/2 phosphorylation<\/td>\nXu et al. Antioxidants. 2023<\/td>\n<\/tr>\n
Berberine (Mahonia marker)<\/td>\nC. acnes mouse-ear acne model<\/td>\n\u2193Ear-tissue IL-6\uff0fIL-1\u03b2\uff0fTNF-\u03b1; reduced ear thickness and colonizing bacterial load<\/td>\nSun et al. Front Microbiol. 2023<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

How to read: the above are published ingredient-level studies (Grade B) covering cell, zebrafish and mouse in vivo models; they support the mechanistic division of labor of ingredients in the formula and are not equivalent to finished-product human efficacy conclusions for AcneZero. A baicalin rabbit-ear acne study (Yang et al. 2019) provides parallel evidence for flavonoid anti-inflammation.<\/p>\n

Full citations are listed in the References at the end ([6][12][13][15][4][17]).<\/p>\n

Axis 3 \u00b7 Oxidative-Stress Management: Protecting Sebum from Oxidation<\/h3>\n

03 THE FIVE AXES \uff5c AXIS 3 \u00b7 OXIDATIVE DEFENSE<\/p>\n

Squalene peroxidation is the amplifier connecting “oiliness” and “inflammation.” AcneZero’s antioxidant axis is built on four polyphenol systems \u2014 silymarin, bioflavonoids, olive leaf and stevia \u2014 with literature evidence covering free-radical scavenging, antioxidant-enzyme upregulation and lipid-peroxidation inhibition.<\/p>\n

Silymarin<\/b>\uff5c Grade BA classic flavonolignan antioxidant. A human study of a silymarin-containing antioxidant serum showed reduced skin lipid peroxidation, plus improvement in acne-related erythema and post-inflammatory hyperpigmentation (J Drugs Dermatol, 2024). \u2192 Human clinical data in Chapter 4 (Silymarin)<\/p>\n

Stevioside<\/b>\uff5c Grade BAt 250 \u03bcM in cell models, stevioside significantly reduced ROS and MDA (a lipid-peroxidation marker) while upregulating T-SOD, CAT and GSH-Px antioxidant enzymes, and inhibited NF-\u03baB\uff0fERK1\/2 phosphorylation (Antioxidants, 2023).<\/p>\n

Olive-leaf polyphenols + bioflavonoids<\/b>\uff5c Grade B\/COleuropein reduced ROS in a UVB model (Grade-C extrapolation; literature species Olea europaea); the ortho-dihydroxyl structure of bioflavonoids confers strong radical-scavenging capacity, with efficiency linked to the C2\u2013C3 double bond and 4-carbonyl features (structure\u2013activity review, 1999).<\/p>\n

Breaking the vicious cycle:<\/b> the antioxidant axis directly reduces the formation of squalene-peroxidation substrates \u2014 lowering the upstream drive of abnormal keratinization while cutting the continuous fuel that oxidized lipids supply to the inflammatory cascade. This is the structural difference between AcneZero and “oil-control-only, sterilization-only” solutions.<\/p>\n

Sources: J Drugs Dermatol. 2024;23(4). DOI:10.36849\/JDD.8120; Xu Q, et al. Antioxidants (Basel). 2023;12(5):1070. DOI:10.3390\/antiox12051070; Zhang DQ, et al. Food and Fermentation Industries. 1999;25(6):52-57; Kim J, et al. 2026<\/p>\n

Axis 4 \u00b7 Microbiome Management: A Non-Antibiotic Antimicrobial Pathway<\/h3>\n

03 THE FIVE AXES \uff5c AXIS 4 \u00b7 MICROBIOME BALANCE<\/p>\n

<\/p>\n

Data redrawn from the original table of Sun et al. 2023 (4 strains including ATCC reference and clinical isolates); inhibition-zone diameters 32.07\u201335.27 mm. The reference antibiotic doxycycline in the same study had an MIC of 0.31 \u03bcg\/mL \u2014 berberine is a plant-derived, non-antibiotic molecule whose value lies in avoiding the antibiotic-resistance narrative.<\/p>\n

Beyond inhibition: biofilms and in vivo validation<\/b>\u25cf Anti-biofilm<\/b>: 10\u201360 \u03bcM berberine concentration-dependently inhibited C. acnes growth and biofilm formation, and downregulated cell-wall synthesis genes murC\uff0fmurD\uff0fmraY\uff0fmurG (Front Microbiol, 2023; J Inflamm Res, 2025);\u25cf In vivo model<\/b>: in a C. acnes mouse-ear model, berberine reduced ear thickness, ear weight and colonizing bacterial load, with ear-tissue IL-6\uff0fIL-1\u03b2\uff0fTNF-\u03b1 declining in parallel;\u25cf Tanshinone synergy<\/b>: a review reports tanshinones’ inhibitory and anti-biofilm activity against C. acnes (including resistant strains) (Fitoterapia, 2025);\u25cf Silymarin support<\/b>: improvements in lesions and microbiome-related indices were observed in human studies (see Chapter 4).<\/p>\n

From “sterilization” to “microbiome balance”:<\/b> modern dermatology no longer pursues total sterilization, but manages C. acnes overgrowth and biofilms. A plant-derived, multi-target antimicrobial strategy is consistent with this philosophy \u2014 and does not constitute an antibiotic-type claim.<\/p>\n

Sources: Sun L, et al. Front Microbiol. 2023;14:1276383. DOI:10.3389\/fmicb.2023.1276383 (in vitro + mouse-ear model, Grade B); J Inflamm Res. 2025 (SZ95 cells, Grade B); Zhang T, et al. Fitoterapia. 2025 (review). Ingredient literature data, not measured on this product.<\/p>\n

Axis 5 \u00b7 Soothing & Barrier: The Safety Foundation of Blemish Care<\/h3>\n

03 THE FIVE AXES \uff5c AXIS 5 \u00b7 SOOTHING & BARRIER<\/p>\n

The problem: the barrier of blemish-prone skin is inherently fragile.<\/b> In vivo research shows that TEWL (transepidermal water loss) is significantly higher in acne-prone skin than in healthy skin \u2014 the stratum corneum barrier is impaired (Pharmaceuticals, 2023). This means an anti-blemish ingredient that adds irritation would instead worsen redness and discomfort: mildness is not a bonus, but the entry ticket.<\/p>\n

AcneZero’s triple barrier-friendly design<\/b>\u25cf Stevia (stevioside)<\/b>\uff5c Grade B: upregulates tight-junction proteins claudin-1, occludin and ZO-1, supporting barrier integrity (Antioxidants, 2023);\u25cf Phospholipid system<\/b>\uff5c Grade A\/B: a skin-lipid-homologous, skin-friendly structure combining active carrying with barrier care;\u25cf Glycerin\u2013propylene glycol humectant base<\/b>\uff5c Grade A: a classic humectant pair that relieves the dryness and flaking common in blemish-prone skin.<\/p>\n\n\n\n
0Skin irritation(MSDS conclusion: no skin irritation)<\/td>\n0Eye irritation(MSDS conclusion: no eye irritation)<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

Product-owned safety data \uff5c Grade A \u00b7 Source: PuriPharm AcneZero MSDS v1.1 \u2014 one of the few Grade-A (product-owned) data points in this material.<\/p>\n

What this means for formulators:<\/b>\u00b7 Suitable for formulas positioned for sensitive, blemish-prone skin and long-term daily care;\u00b7 The soothing narrative is backed by ingredient-level barrier literature, not just a “mildness claim”;\u00b7 Together with the sebum, inflammation, oxidation and microbiome axes, it completes a full care loop.<\/p>\n

Sources: Condr\u00f2 G, et al. Pharmaceuticals (Basel). 2023;16(12):1704 (TEWL background); Xu Q, et al. Antioxidants (Basel). 2023;12(5):1070 (tight-junction proteins, Grade B); AcneZero MSDS v1.1 (safety, Grade A).<\/p>\n

04<\/b><\/p>\n

Botanical Actives in Focus<\/h2>\n

Seven botanicals, seven scientific profiles: botanical origin, marker actives, key literature evidence, and each one’s role in the five-axis system.<\/p>\n

In this chapter \uff5c Bioflavonoids \u00b7 Salvia \u00b7 Silymarin \u00b7 Olive leaf \u00b7 Mahonia \u00b7 Gardenia fruit \u00b7 Stevia<\/p>\n

Bioflavonoids: Dual Inflammation\u2013Oxidation Management from the Polyphenol Family<\/h3>\n

04 BOTANICAL ACTIVES \uff5c BIOFLAVONOIDS<\/p>\n

<\/p>\n

Citrus fruits are a classic source of bioflavonoids (illustrative image)<\/p>\n\n\n\n\n\n
INCI<\/td>\nBioflavonoids<\/td>\n<\/tr>\n
CAS<\/td>\n61788-55-4<\/td>\n<\/tr>\n
Role in system<\/td>\nDual support: inflammation \u00b7 oxidation<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

Structure determines activity:<\/b> flavonoids’ radical-scavenging capacity is directly tied to molecular structure \u2014 the C2\u2013C3 double bond, the 4-carbonyl group and ortho-dihydroxyl groups are the key features of efficient scavengers; the ranking follows a clear structure\u2013activity relationship (e.g., rutin > quercetin > morin > hesperidin, system-dependent).<\/p>\n

Quercetin: direct evidence in acne-inflammation models<\/b>\uff5c Grade BIn C. acnes-stimulated keratinocytes and immune cells it inhibited cytokines and downregulated TLR2\uff0fMAPK\uff0fMMP-9, with in vivo validation in a mouse-ear model (Int Immunopharmacol, 2021).<\/p>\n

Baicalin: parallel evidence in a rabbit-ear acne model<\/b>\uff5c Grade BRNA-seq showed baicalin reduced rabbit-ear acne lesions, lowered serum TNF-\u03b1\uff0fIL-1\u03b2\uff0fIL-6\uff0fIL-8, and broadly suppressed TNF signaling (J Tradit Chin Med Sci, 2019).<\/p>\n

Why flavonoids are the “infrastructure” of anti-blemish blends:<\/b> one molecular family covers both radical scavenging (Axis 3) and inflammatory-signal inhibition (Axis 2), with structural diversity, wide sourcing and a long safety record \u2014 making bioflavonoids a natural hub connecting the axes. The human anti-acne study of EGCG (J Invest Dermatol, 2013) further proves the clinical feasibility of the polyphenol pathway.<\/p>\n

Sources: Zhang DQ, Tai JX, Fu Q. Research and application of bioflavonoids. Food and Fermentation Industries. 1999;25(6):52-57; Lim HJ, et al. 2021; Yang X, et al. J Tradit Chin Med Sci. 2019;6(3):201-210; Yoon JY, et al. 2013 (all Grade-B ingredient literature)<\/p>\n

Salvia Miltiorrhiza Extract: A Dual Blockade of Microbes and Inflammation<\/h3>\n

04 BOTANICAL ACTIVES \uff5c SALVIA MILTIORRHIZA<\/p>\n

<\/p>\n

Dried Salvia miltiorrhiza root (illustrative image)<\/p>\n\n\n\n\n\n
INCI<\/td>\nSalvia Miltiorrhiza Extract<\/td>\n<\/tr>\n
CAS<\/td>\n90106-50-6<\/td>\n<\/tr>\n
Role in system<\/td>\nDual axes: microbiome \u00b7 inflammation<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

Marker actives:<\/b> tanshinones (lipophilic diterpene quinones) and salvianolic acids (water-soluble phenolic acids).<\/p>\n

Microbiome axis<\/b>\uff5c Grade B\u3000A 2025 Fitoterapia review systematically summarized tanshinones’ molecular mechanisms against acne, including inhibitory activity against C. acnes (including resistant strains) and anti-biofilm effects \u2014 together with berberine forming the product’s plant-derived antimicrobial combination.<\/p>\n

Inflammation axis<\/b>\uff5c Grade B\u3000Tanshinone IIA concentration-dependently inhibited MCP-1, IL-6, TNF-\u03b1 and NO via the TLR4\uff0fTAK1\uff0fNF-\u03baB pathway (Int J Mol Med, 2019).<\/p>\n

Tanshinone IIA’s interception levels in inflammatory signaling<\/b><\/p>\n

\u2193 TLR4 \u2192 \u2193 p-TAK1 \u2192 \u2193 NF-\u03baB nuclear translocation \u2192 \u2193 Inflammatory factors<\/p>\n

Reading the diagram: tanshinone IIA suppresses three levels simultaneously \u2014 receptor (TLR4), kinase (TAK1) and transcription factor (NF-\u03baB). This is the “multi-interception-point” design embodied within a single ingredient (Meng et al. 2019, LPS cell model).<\/p>\n

Sources: Zhang T, et al. Tanshinone in acne therapeutics. Fitoterapia. 2025 (review); Meng Z, et al. Int J Mol Med. 2019;43(4):1847-1858. DOI:10.3892\/ijmm.2019.4100 (Grade-B ingredient literature)<\/p>\n

Silymarin: The Antioxidant Mainstay with Human Clinical Data<\/h3>\n

04 BOTANICAL ACTIVES \uff5c SILYMARIN<\/p>\n

<\/p>\n

Data redrawn from J Drugs Dermatol. 2024: lesion and oiliness endpoints from the monotherapy study (n=56, 12 weeks); erythema \/ dryness \/ scaling from the combination-regimen tolerability study (n=40). The studies also reported reduced lipid peroxidation and improved post-inflammatory hyperpigmentation.<\/p>\n

<\/p>\n

Milk thistle (Silybum marianum)<\/p>\n

A second human study (0.5% silymarin serum):<\/b> 22 subjects with mild-to-moderate acne, 4 weeks: mGAGS score, lesion counts and melanin index decreased significantly, with no adverse events (J Cosmet Dermatol, 2023).<\/p>\n

Role in AcneZero:<\/b>\u25cf The human-evidence anchor of the oxidative-stress axis: anti-lipid-peroxidation maps directly onto the squalene-peroxidation mechanism;\u25cf The melanin-index reduction connects to the post-blemish tone-care narrative (see Chapter 5);\u25cf Its typical value in the ingredient list is 0.5% \u2014 the same order of magnitude as the concentrations used in clinical studies (Grade-A formula fact).<\/p>\n

Sources: A silymarin antioxidant serum improves facial acne alone and as part of a treatment regimen. J Drugs Dermatol. 2024;23(4). DOI:10.36849\/JDD.8120; Kim J, et al. J Cosmet Dermatol. 2023;22(2):561-568. DOI:10.1111\/jocd.15439 (Grade-B ingredient literature, not clinical data on this product)<\/p>\n

Olive Leaf Extract: A Polyphenol Carrier for Sebum\u2013Inflammation Dual Regulation<\/h3>\n

04 BOTANICAL ACTIVES \uff5c OLIVE LEAF<\/p>\n

<\/p>\n

Olive branches and leaves (illustrative image)<\/p>\n\n\n\n\n\n
INCI<\/td>\nCanarium Album Leaf Extract<\/td>\n<\/tr>\n
CAS<\/td>\n\u2014<\/td>\n<\/tr>\n
Role in system<\/td>\nSebum \u00b7 inflammation \u00b7 oxidation<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

Sebocyte evidence<\/b>\uff5c Grade C (literature species Olea europaea, extrapolation reference)A 2026 study (SEB-1 human sebocytes): olive leaf extract significantly inhibited linoleic-acid-induced lipid accumulation without cytotoxicity; downregulated AKT\uff0fERK phosphorylation and PPAR-\u03b3\uff0fSREBP-1 expression; and reduced IL-8, TNF-\u03b1 and PGE2 in C. acnes- or UVB-stimulated HaCaT keratinocytes (Curr Issues Mol Biol, 2026).<\/p>\n

Antioxidant evidence for the marker compound oleuropein<\/b>\uff5c Grade CProteomics showed oleuropein downregulated pro-inflammatory cytokines and upregulated antioxidant defenses in H\u2082O\u2082-stimulated HaCaT cells (2025); oleuropein and hydroxytyrosol are skin-permeable elastase\uff0fcollagenase inhibitors with synergistic antioxidant activity in human dermal fibroblasts (Int J Food Sci Nutr, 2022).<\/p>\n

Evidence boundary (scientific integrity):<\/b>\u00b7 The in vitro studies above used Olea europaea leaf; this product uses Canarium album leaf extract, and the data serve as a reference from related olive-leaf polyphenol research (Grade-C reasonable extrapolation), not as direct measurements on this ingredient in the product;\u00b7 In the same study, no direct antibacterial activity was detected for this extraction process \u2014 the product therefore positions olive leaf for sebum regulation, anti-inflammation and antioxidant support, while the microbiome axis is carried by Mahonia, Salvia and silymarin;\u00b7 This is exactly the point of the five-axis division of labor: let each ingredient do what its evidence does best.<\/p>\n

Sources: Kim J, et al. Curr Issues Mol Biol. 2026;48(6):549. DOI:10.3390\/cimb48060549; Li H, et al. Int J Food Sci Nutr. 2022;73(4):460-470; INCI information: AcneZero Ingredient List (Grade A)<\/p>\n

Mahonia Fortunei: The Botanical Source of Berberine<\/h3>\n

04 BOTANICAL ACTIVES \uff5c MAHONIA<\/p>\n

<\/p>\n

Mahonia plant (image source: Wikimedia Commons)<\/p>\n\n\n\n\n\n
INCI<\/td>\nMahonia Fortunei (Chinese mahonia) Extract<\/td>\n<\/tr>\n
CAS<\/td>\n\u2014<\/td>\n<\/tr>\n
Role in system<\/td>\nCore of the microbiome axis<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

Botanical basis (patent literature):<\/b> Chinese patent CN1069493A records that Mahonia (Berberidaceae) rhizomes contain 1.5\u20132.4%<\/b> berberine, and the refining process described therein achieves 98.1%<\/b> berberine purity \u2014 a clear documentary basis for Mahonia as a botanical source of berberine.<\/p>\n

Berberine’s anti-acne evidence:<\/b> in vitro MIC 6.25\u201312.5 \u03bcg\/mL, anti-biofilm activity, downregulation of cell-wall synthesis genes, and anti-inflammatory effects in a mouse-ear model (see Chapter 3, Axis 4); inhibition of lipid synthesis and NF-\u03baB in SZ95 sebocytes (see Chapter 3, Axis 1).<\/p>\n

Same-genus support<\/b>\uff5c Grade B: bisbenzylisoquinoline alkaloids from Mahonia aquifolium show lipoxygenase (LOX) inhibition and anti-lipid-peroxidation activity, highly correlated with each other (r=0.9533) \u2014 suggesting the genus’s alkaloids combine microbiome-management and antioxidant potential (Pharmazie, 1996).<\/p>\n

Sources: Liao ZJ. Process for extracting and refining berberine from Mahonia. Chinese patent CN1069493A, published 1993-03-03; Bez\u00e1kov\u00e1 L, et al. Pharmazie. 1996;51(10):758-761; Sun L, et al. 2023; J Inflamm Res. 2025 (Grade-B ingredient literature)<\/p>\n

Gardenia Fruit Extract: The Bridge from Anti-Inflammation to Post-Blemish Care<\/h3>\n

04 BOTANICAL ACTIVES \uff5c GARDENIA FRUIT<\/p>\n

<\/p>\n

Dried gardenia fruits (illustrative image)<\/p>\n\n\n\n\n\n
INCI<\/td>\nGardenia Jasminoides Fruit Extract<\/td>\n<\/tr>\n
CAS<\/td>\n92457-01-7<\/td>\n<\/tr>\n
Role in system<\/td>\nInflammation axis \u00b7 post-blemish care<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

Gardenia fruit extract (GJE)<\/b>\uff5c Grade B\u3000Significantly inhibited LPS-induced IL-1\u03b2, IL-6 and TNF-\u03b1 release via TLR4\uff0fNKAP signaling downregulation, with anti-inflammatory activity validated in an in vivo zebrafish model (Exp Ther Med, 2021).<\/p>\n

Geniposide (marker compound)<\/b>\uff5c Grade B\u3000Acts downstream of TLR4 to inhibit NF-\u03baB p65 and MAPK pathways, exerting anti-inflammatory effects in animal inflammation models (Inflammation, 2014).<\/p>\n

Crocetin (gardenia-derived active)<\/b>\uff5c Grade B\u3000In B16F10 melanoma cells it inhibited tyrosinase activity and melanin synthesis, downregulated tyrosinase and MITF proteins and scavenged ROS \u2014 pointing to the post-inflammatory hyperpigmentation (PIH) management chain (Anticancer Agents Med Chem, 2018).<\/p>\n\n\n\n\n
Gardenia fruit’s “two-phase” value: acute and recovery<\/th>\n<\/tr>\n
Acute phase (inflammation management)GJE \/ geniposide inhibit the TLR4\u2013NF-\u03baB\uff0fMAPK cascade, reducing IL-1\u03b2\uff0fIL-6\uff0fTNF-\u03b1 release and easing the driving signals of redness and swelling.<\/td>\nRecovery phase (post-blemish care)Crocetin inhibits the tyrosinase\u2013MITF axis and scavenges ROS, intervening upstream of melanin synthesis in the dark-mark formation chain (see Chapter 5).<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

Sources: Chen J, et al. Exp Ther Med. 2021;22(1):700. DOI:10.3892\/etm.2021.10132; Song X, et al. Inflammation. 2014;37:1588-1598; Hashemi-Shahri S, et al. Anticancer Agents Med Chem. 2018 (Grade-B ingredient literature)<\/p>\n

Stevia Leaf\/Stem Extract: A Sweet Answer for Barrier and Soothing<\/h3>\n

04 BOTANICAL ACTIVES \uff5c STEVIA<\/p>\n

<\/p>\n

Stevia rebaudiana plant (illustrative image)<\/p>\n\n\n\n\n\n
INCI<\/td>\nStevia Rebaudiana Leaf\/Stem Extract<\/td>\n<\/tr>\n
CAS<\/td>\n91722-21-3<\/td>\n<\/tr>\n
Role in system<\/td>\nBarrier \u00b7 soothing \u00b7 antioxidant<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

Stevioside (marker compound)<\/b>\uff5c Grade B\u3000At 250 \u03bcM in cell models, stevioside showed a triple “antioxidant + anti-inflammatory + barrier” effect:\u00b7 Antioxidant: \u2193ROS, \u2193MDA; \u2191T-SOD, \u2191CAT, \u2191GSH-Px;\u00b7 Anti-inflammatory: \u2193IL-6, \u2193IL-8, \u2193TNF-\u03b1; \u2193NF-\u03baB\uff0fI\u03baB\uff0fERK1\/2 phosphorylation;\u00b7 Barrier: \u2191claudin-1, \u2191occludin, \u2191ZO-1 tight-junction proteins (Antioxidants, 2023).<\/p>\n

Immunomodulatory support<\/b>\uff5c Grade B\u3000Stevioside activates AMPK and suppresses macrophage inflammatory responses (Molecules, 2021); 1 mM stevioside inhibited NF-\u03baB in LPS-stimulated THP-1 cells (summarized in a 2023 review).<\/p>\n

Why stevia is the “finishing ingredient” of the five-axis system:<\/b> what anti-blemish formulas most often overlook is user experience and barrier consequences. With the highest typical value among the botanicals in the ingredient list (5%), stevia leaf\/stem extract carries the soothing and barrier-support role: tight-junction upregulation directly answers the impaired-barrier fact of elevated TEWL in blemish-prone skin, closing the loop of “efficacy” and “mildness” within one formula.<\/p>\n

Sources: Xu Q, et al. Antioxidants (Basel). 2023;12(5):1070. DOI:10.3390\/antiox12051070; Wei F, et al. Molecules. 2021;26(4):858; content: AcneZero Ingredient List (Grade A)<\/p>\n

05<\/b><\/p>\n

Synergy \u00b7 Claims \u00b7 Applications<\/h2>\n

Translating ingredient evidence into market language: the synergy matrix, an evidence-graded claims system, the post-blemish care chain and application scenarios \u2014 every claim traceable to its source.<\/p>\n

In this chapter \uff5c 7 botanicals \u00d7 5 axes synergy matrix \u00b7 Claims & evidence grading \u00b7 Post-blemish care \u00b7 Applications \u00b7 B2B value<\/p>\n

Seven Botanicals \u00d7 Five Axes: The Synergy Matrix at a Glance<\/h3>\n

05 SYNERGY\u00b7CLAIMS\u00b7APPLICATIONS \uff5c SYNERGY MATRIX<\/p>\n\n\n\n\n\n\n\n\n\n\n
Ingredient<\/th>\nA1 Sebum<\/th>\nA2 Inflammation<\/th>\nA3 Oxidation<\/th>\nA4 Microbiome<\/th>\nA5 Barrier & soothing<\/th>\n<\/tr>\n
Mahonia (berberine)<\/td>\n\u25cf<\/td>\n\u25cf<\/td>\n\u25cb<\/td>\n\u25cf<\/td>\n<\/td>\n<\/tr>\n
Salvia (tanshinones)<\/td>\n<\/td>\n\u25cf<\/td>\n\u25cb<\/td>\n\u25cf<\/td>\n<\/td>\n<\/tr>\n
Silymarin<\/td>\n\u25cb<\/td>\n\u25cb<\/td>\n\u25cf<\/td>\n\u25cb<\/td>\n\u25cf<\/td>\n<\/tr>\n
Olive leaf (polyphenols)<\/td>\n\u25cf<\/td>\n\u25cf<\/td>\n\u25cf<\/td>\n<\/td>\n<\/td>\n<\/tr>\n
Bioflavonoids<\/td>\n<\/td>\n\u25cf<\/td>\n\u25cf<\/td>\n\u25cb<\/td>\n<\/td>\n<\/tr>\n
Gardenia fruit (geniposide \/ crocetin)<\/td>\n<\/td>\n\u25cf<\/td>\n\u25cb<\/td>\n<\/td>\n\u25cf<\/td>\n<\/tr>\n
Stevia (stevioside)<\/td>\n<\/td>\n\u25cb<\/td>\n\u25cf<\/td>\n<\/td>\n\u25cf<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

\u25cf Ingredient-level literature evidence for that axis (mainly Grade B; Grade-C extrapolation for olive leaf)\u3000\u25cb Indirect or auxiliary support (e.g., same-genus evidence, review support, associated endpoints in human studies)\u3000\u2014\u3000The matrix summarizes the literature cited in Chapters 3\u20134; it is not the result of finished-product efficacy testing.<\/p>\n

Matrix source: all ingredient literature cited in this material (see References); composition: AcneZero Ingredient List (Grade A).<\/p>\n

The Claims System: Every Claim Has Its Evidence Coordinates<\/h3>\n

05 SYNERGY\u00b7CLAIMS\u00b7APPLICATIONS \uff5c CLAIMS & EVIDENCE GRADING<\/p>\n\n\n\n\n\n\n\n\n\n
Market claim (cosmetics framework)<\/th>\nSupporting logic<\/th>\nKey sources<\/th>\nGrade<\/th>\n<\/tr>\n
Oil Control<\/td>\nBerberine inhibits FASN\uff0fDGAT1 and lipid secretion in sebocytes; olive leaf modulates SREBP-1\uff0fPPAR-\u03b3 (Grade-C extrapolation)<\/td>\nJ Inflamm Res. 2025; CIMB. 2026<\/td>\nB\uff0fC<\/td>\n<\/tr>\n
Blemish-Prone Skin Care<\/td>\nBerberine in vitro MIC\uff0fMBC, anti-biofilm and mouse-ear model; tanshinone antimicrobial review<\/td>\nFront Microbiol. 2023; Fitoterapia. 2025<\/td>\nB<\/td>\n<\/tr>\n
Soothing<\/td>\nQuercetin, tanshinone IIA, gardenia fruit and stevioside inhibit the TLR\u2013NF-\u03baB cascade at multiple levels<\/td>\nSee the evidence matrix in Chapter 3<\/td>\nB<\/td>\n<\/tr>\n
Antioxidant Defense<\/td>\nSilymarin human study reduces lipid peroxidation; stevioside \u2191antioxidant enzymes; flavonoid structure\u2013activity relationship<\/td>\nJDD. 2024; Antioxidants. 2023<\/td>\nB<\/td>\n<\/tr>\n
Microbiome Balance<\/td>\nNon-antibiotic, plant-derived antimicrobial strategy managing C. acnes overgrowth and biofilms<\/td>\nFront Microbiol. 2023<\/td>\nB<\/td>\n<\/tr>\n
Barrier Support + Post-Blemish Tone Care<\/td>\nStevioside upregulates tight-junction proteins; silymarin human study improves melanin index; crocetin inhibits tyrosinase<\/td>\nAntioxidants. 2023; J Cosmet Dermatol. 2023<\/td>\nB<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

Evidence grading: A = AcneZero’s own product data (MSDS safety, ingredient list); B = published ingredient literature (cell \/ animal \/ human, models as stated in the original papers); C = reasonable extrapolation from ingredient information. Finished-product efficacy verification is recommended before making finished-product claims.<\/p>\n

Claim boundary: the above is a cosmetics efficacy narrative framework (blemish-prone skin care \/ oil control \/ soothing \/ microbiome balance \/ antioxidant \/ barrier & post-blemish tone care) and does not constitute drug or therapeutic claims.<\/p>\n

The Post-Blemish Care Chain: Full Coverage from Inflammation to Dark Marks<\/h3>\n

05 SYNERGY\u00b7CLAIMS\u00b7APPLICATIONS \uff5c POST-BLEMISH CARE<\/p>\n

The formation chain of post-inflammatory hyperpigmentation (PIH) and its intervention points<\/p>\n

Inflammatory cascade (IL\uff0fTNF-\u03b1) \u2192 Oxidative-stress amplification \u2192 Tyrosinase\uff0fMITF activation \u2192 Melanin deposition \u00b7 dark marks<\/p>\n

Intervention point \u2460: silymarin (human evidence)<\/b>In a 4-week human study of a 0.5% silymarin serum (n=22), acne severity scores and lesion counts fell while the skin melanin index decreased significantly (J Cosmet Dermatol, 2023); a 2024 human study (n=56) reported improved post-inflammatory hyperpigmentation and reduced lipid peroxidation (J Drugs Dermatol, 2024).<\/p>\n

Intervention point \u2461: crocetin (mechanistic evidence)<\/b>Gardenia-derived crocetin inhibited tyrosinase activity and reduced melanin synthesis in B16F10 cells, downregulated tyrosinase and MITF protein expression and scavenged ROS \u2014 intervening upstream of melanin synthesis in dark-mark formation (Anticancer Agents Med Chem, 2018).<\/p>\n

The complete narrative:<\/b> inflammation management (Axis 2) reduces the upstream drive of PIH, antioxidant defense (Axis 3) blocks the amplification step, and silymarin plus gardenia provide human and mechanistic evidence for dark-mark care \u2014 AcneZero places “fighting acne” and “post-blemish recovery” within the same ingredient logic, giving brands a full-cycle product story from the acute phase to recovery.<\/p>\n

Sources: Kim J, et al. J Cosmet Dermatol. 2023;22(2):561-568; J Drugs Dermatol. 2024;23(4). DOI:10.36849\/JDD.8120; Hashemi-Shahri S, et al. Anticancer Agents Med Chem. 2018 (Grade-B ingredient literature)<\/p>\n

Applications: From the Facial Core to Extended Scenarios<\/h3>\n

05 SYNERGY\u00b7CLAIMS\u00b7APPLICATIONS \uff5c APPLICATIONS<\/p>\n\n\n\n\n
Facial care (core scenario)<\/th>\nBody care<\/th>\nScalp care (extended research direction)<\/th>\n<\/tr>\n
\u00b7 Blemish-care serum: the lead format for the full five-axis story\u00b7 Oil-control lotion \/ gel: sebum management + microbiome balance\u00b7 Soothing repair mask: inflammation management + barrier support\u00b7 Post-blemish tone-care serum: the silymarin + gardenia PIH evidence chain\u00b7 Targeted spot care: high-concentration multi-pathway positioning<\/td>\n\u00b7 Back \/ chest blemish care: sebaceous-dense areas \u2014 a natural extension of the oil-control + microbiome narrative\u00b7 Body mist \/ toner: water solubility suits large-area formats (Grade-A formula fact: water-soluble at 20\u00b0C)\u00b7 Post-workout refreshing care: oil and microbiome management scenarios<\/td>\n\u00b7 The scalp is likewise a sebum- and microbe-dominated ecosystem: Malassezia-mediated sebum peroxidation products (squalene monohydroperoxide, MDA) are among the triggers of dandruff (literature background)\u00b7 AcneZero’s sebum-management, antioxidant and microbiome ingredient logic is mechanistically transferable to scalp scenarios\u00b7 Positioning note: this is an extended research direction based on published literature; the MSDS defines the product’s use as a cosmetic skincare ingredient, and scalp applications require separate evaluation and validation<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

Formulation fit:<\/b> the water-based (water-soluble) vehicle suits serums, toners, masks and gels; recommended pH, heat\/light stability and specific compatibility parameters should be confirmed with the PuriPharm technical team \u2014 this material does not invent a recommended dosage.<\/p>\n

Scalp background: DeAngelis YM, et al. J Investig Dermatol Symp Proc. 2005;10(3):295-297; product use and solubility: AcneZero MSDS v1.1 (Grade A).<\/p>\n

B2B Partnership Value: A One-Stop, Multi-Pathway Anti-Blemish Solution<\/h3>\n

05 SYNERGY\u00b7CLAIMS\u00b7APPLICATIONS \uff5c PARTNERSHIP VALUE<\/p>\n\n\n\n\n
For brands: a complete science story<\/th>\nFor formulators: clear engineering parameters<\/th>\nRegulatory & documentation support<\/th>\n<\/tr>\n
\u00b7 The five-axis mechanism + synergy matrix converts directly into product-page and detail-page storytelling\u00b7 Every claim carries an evidence grade, standing up to regulatory and platform review\u00b7 A full-cycle product-line imagination “from the acute phase to post-blemish recovery”<\/td>\n\u00b7 Water-soluble (20\u00b0C), friendly to water-based formats\u00b7 4\u201325\u00b0C light-protected storage, routine supply-chain management\u00b7 MSDS data showing no skin and no eye irritation, reducing the safety-assessment burden (Grade A)<\/td>\n\u00b7 Listed in China’s Inventory of Existing Chemical Substances (IECIC)\u00b7 Complete INCI \/ CAS information; transparent, traceable ingredient list\u00b7 MSDS v1.1 and supporting technical documents for export and multi-market compliance assessment\u00b7 The ingredient literature pack (References) supports claim filing and content review<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

CONTACT \uff5c Business & Technical Inquiries<\/p>\n

PuriPharm Co., Ltd.Web\u3000www.puriactives.comEmail\u3000service@puripharm.comTel\u3000+86-572-2745768Address\u30007F, Building 6E, No. 1366 Hongfeng Road, Huzhou, Zhejiang, China<\/p>\n

Product specifications and regulatory information: AcneZero MSDS v1.1 (Grade A); contact details: official company materials. Please contact the technical team for recommended dosage and finished-product efficacy verification plans.<\/p>\n

References & Documentary Basis<\/h3>\n

REFERENCES<\/p>\n

    \n
  1. Cong TX, Hao D, Wen X, et al. From pathogenesis of acne vulgaris to anti-acne agents. Arch Dermatol Res. 2019;311(5):337-349. DOI:10.1007\/s00403-019-01908-x<\/li>\n
  2. Dr\u00e9no B, et al. Cutibacterium acnes and acne vulgaris: a brief look at the latest updates. J Eur Acad Dermatol Venereol. 2018;32(Suppl 2):5-14.<\/li>\n
  3. Condr\u00f2 G, Sciortino R, Perugini P. Squalene peroxidation and biophysical parameters in acne-prone skin: a pilot “in vivo” study. Pharmaceuticals (Basel). 2023;16(12):1704. DOI:10.3390\/ph16121704<\/li>\n
  4. Sun L, Yu Q, Peng F, et al. The antibacterial activity of berberine against Cutibacterium acnes: its therapeutic potential in inflammatory acne. Front Microbiol. 2023;14:1276383. DOI:10.3389\/fmicb.2023.1276383<\/li>\n
  5. Berberine inhibits acne-related lipid secretion and inflammation by regulating the hsa-miR-3150a-3p\/TP53 pathway. J Inflamm Res. 2025.<\/li>\n
  6. Lim HJ, Kang SH, Song YJ, et al. Inhibitory effect of quercetin on Propionibacterium acnes-induced skin inflammation. Int Immunopharmacol. 2021;96:107557. DOI:10.1016\/j.intimp.2021.107557<\/li>\n
  7. A silymarin antioxidant serum improves facial acne alone and as part of a treatment regimen. J Drugs Dermatol. 2024;23(4). DOI:10.36849\/JDD.8120<\/li>\n
  8. Kim J, et al. Efficacy and safety of silymarin containing antioxidant serum as an adjuvant treatment of mild-to-moderate acne vulgaris. J Cosmet Dermatol. 2023;22(2):561-568. DOI:10.1111\/jocd.15439<\/li>\n
  9. Yoon JY, Kwon HH, Min SU, et al. Epigallocatechin-3-gallate improves acne in humans by modulating intracellular molecular targets and inhibiting P. acnes. J Invest Dermatol. 2013;133(2):429-440.<\/li>\n
  10. Kim J, Jo YW, Bang WJ, et al. Olive leaf extract suppresses sebogenesis and inflammation via AKT\/ERK and SREBP-1\/PPAR-\u03b3 signaling in human sebocytes. Curr Issues Mol Biol. 2026;48(6):549. DOI:10.3390\/cimb48060549<\/li>\n
  11. Chen J, et al. Anti-inflammatory activities of Gardenia jasminoides extracts in retinal pigment epithelial cells and zebrafish embryos. Exp Ther Med. 2021;22(1):700. DOI:10.3892\/etm.2021.10132<\/li>\n
  12. Song X, et al. Geniposide plays an anti-inflammatory role via regulating TLR4 and downstream signaling pathways in lipopolysaccharide-induced mastitis in mice. Inflammation. 2014;37:1588-1598. DOI:10.1007\/s10753-014-9885-2<\/li>\n
  13. Xu Q, et al. Stevioside improves antioxidant capacity and intestinal barrier function. Antioxidants (Basel). 2023;12(5):1070. DOI:10.3390\/antiox12051070<\/li>\n
  14. Wei F, et al. Stevioside activates AMPK to suppress inflammation in macrophages. Molecules. 2021;26(4):858. DOI:10.3390\/molecules26040858<\/li>\n
  15. Meng Z, Si CY, Teng S, et al. Tanshinone IIA inhibits lipopolysaccharide-induced inflammatory responses through the TLR4\/TAK1\/NF-\u03baB signaling pathway in vascular smooth muscle cells. Int J Mol Med. 2019;43(4):1847-1858. DOI:10.3892\/ijmm.2019.4100<\/li>\n
  16. Zhang T, et al. Tanshinone in acne therapeutics: integrating molecular mechanisms, drug development, and multimodal treatment strategies. Fitoterapia. 2025.<\/li>\n
  17. Yang X, Huang G, You L, et al. High-throughput RNA sequencing reveals the anti-inflammatory mechanism of baicalin on Propionibacterium acnes-induced acne in rabbits. J Tradit Chin Med Sci. 2019;6(3):201-210.<\/li>\n
  18. Bez\u00e1kov\u00e1 L, et al. Lipoxygenase inhibition and antioxidant properties of bisbenzylisoquinoline alkaloids isolated from Mahonia aquifolium. Pharmazie. 1996;51(10):758-761.<\/li>\n
  19. Hashemi-Shahri S, et al. ROS-scavenging and anti-tyrosinase properties of crocetin on B16F10 murine melanoma cells. Anticancer Agents Med Chem. 2018.<\/li>\n
  20. Mezei M, Gulasekharam V. Liposomes \u2014 a selective drug delivery system for the topical route of administration: gel dosage form. Life Sci. 1980;26:1473-1477.<\/li>\n
  21. Li H, et al. Oleuropein and hydroxytyrosol as skin-permeable elastase\/collagenase inhibitors with synergistic antioxidant activity in human skin fibroblasts. Int J Food Sci Nutr. 2022;73(4):460-470.<\/li>\n
  22. DeAngelis YM, et al. Three etiologic facets of dandruff and seborrheic dermatitis: Malassezia fungi, sebaceous lipids, and individual sensitivity. J Investig Dermatol Symp Proc. 2005;10(3):295-297.<\/li>\n
  23. Zhang DQ, Tai JX, Fu Q. Research and application of bioflavonoids. Food and Fermentation Industries. 1999;25(6):52-57. (In Chinese)<\/li>\n
  24. Liao ZJ. Process for extracting and refining berberine from Mahonia. Chinese patent CN1069493A, published 1993-03-03. (In Chinese)<\/li>\n<\/ol>\n

    Internal company documents (Grade-A factual basis): PuriPharm AcneZero MSDS v1.1 (2019-07-13); AcneZero Ingredient List.<\/p>\n

    From single-target anti-acneto multi-pathway blemish-prone skin management.<\/b><\/p>\n

    PuriActives\u00ae AcneZero \u2014 Seven botanicals \u00d7 phospholipid-based active system \u00d7 five axes<\/p>\n

    PuriPharm Co., Ltd. \uff5c INNOVATION FOR HEALTH & BEAUTYwww.puriactives.com \uff5c service@puripharm.com \uff5c +86-572-2745768 \uff5c Huzhou, Zhejiang, China<\/p>\n","protected":false},"excerpt":{"rendered":"

    PuriActives\u00ae AcneZero \u2014 Multi-Pathway Botanical Blemish […]<\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":[],"categories":[25],"tags":[],"_links":{"self":[{"href":"http:\/\/www.puriactives.com\/en\/index.php?rest_route=\/wp\/v2\/posts\/1400"}],"collection":[{"href":"http:\/\/www.puriactives.com\/en\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"http:\/\/www.puriactives.com\/en\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"http:\/\/www.puriactives.com\/en\/index.php?rest_route=\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"http:\/\/www.puriactives.com\/en\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=1400"}],"version-history":[{"count":1,"href":"http:\/\/www.puriactives.com\/en\/index.php?rest_route=\/wp\/v2\/posts\/1400\/revisions"}],"predecessor-version":[{"id":1401,"href":"http:\/\/www.puriactives.com\/en\/index.php?rest_route=\/wp\/v2\/posts\/1400\/revisions\/1401"}],"wp:attachment":[{"href":"http:\/\/www.puriactives.com\/en\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=1400"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"http:\/\/www.puriactives.com\/en\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=1400"},{"taxonomy":"post_tag","embeddable":true,"href":"http:\/\/www.puriactives.com\/en\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=1400"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}